FDA staff focus on Onyx cancer drug’s side effects

WASHINGTON (Reuters) – U.S. drug reviewers said the serious heart, lung and liver side effects of Onyx Pharmaceuticals Inc’s carfilzomib drug may outweigh the drug’s benefits for multiple myeloma patients.